Discover why Abbott Laboratories (ABT) earns a buy rating with strong fundamentals, dividend growth, and growth prospects.

Get the live share price of EXACT Sciences Corporation (EXAS), including intraday charts, historical performance, key financials, and market updates. Track the latest US stock market activity.

Explore Russell 1000 companies reaching new 52-week highs with price data and volume metrics on The Economic Times.

Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as ...

Below is Validea's guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow, EXAS rates highest using our P/B Growth Investor model based on the published strategy ...

The company plans to use the proceeds to expand its commercial and data infrastructure to support the launch of multiple blood-based cancer detection tests.

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 15 years by 9.5% on an annualized basis producing an average annual return of 21.58%. Currently, Exact Sciences has a market ...

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 15 years by 8.51% on an annualized basis producing an average annual return of 20.65%. Currently, Exact Sciences has a market ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...